Literature DB >> 17524628

Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.

Aoife Hunt1, Peter Schönknecht, Marcus Henze, Ulrich Seidl, Uwe Haberkorn, Johannes Schröder.   

Abstract

While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate cortices has been demonstrated in Alzheimer's disease (AD) compared with controls, cerebral glucose metabolism in patients with mild cognitive impairment who subsequently develop AD is less well-defined. In the present study we measured cerebral glucose metabolism by positron emission tomography (PET) with (18)F-2-fluoro-2-deoxy-D-glucose in 14 patients with aging-associated cognitive decline (AACD), 44 patients with AD, and 14 healthy control subjects at baseline. The AACD patients were clinically followed up, and conversion to AD was determined. Compared with controls, AACD patients had significantly reduced glucose metabolism in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices, while the respective deficits were more pronounced in AD patients and also involved the frontal cortices. AACD patients who subsequently converted to AD (AACD-converters) showed more extended metabolic changes which also involved the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17524628     DOI: 10.1016/j.pscychresns.2006.12.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  40 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 2.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

3.  Structural and functional biomarkers of prodromal Alzheimer's disease: a high-dimensional pattern classification study.

Authors:  Yong Fan; Susan M Resnick; Xiaoying Wu; Christos Davatzikos
Journal:  Neuroimage       Date:  2008-03-06       Impact factor: 6.556

4.  Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia.

Authors:  Rosebud O Roberts; Lewis A Roberts; Yonas E Geda; Ruth H Cha; V Shane Pankratz; Helen M O'Connor; David S Knopman; Ronald C Petersen
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 5.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

6.  Glucose controls nuclear accumulation, promoter binding, and transcriptional activity of the MondoA-Mlx heterodimer.

Authors:  Christopher W Peterson; Carrie A Stoltzman; Michael P Sighinolfi; Kyoung-Sim Han; Donald E Ayer
Journal:  Mol Cell Biol       Date:  2010-04-12       Impact factor: 4.272

Review 7.  The effect of aging on brain barriers and the consequences for Alzheimer's disease development.

Authors:  Nina Gorlé; Caroline Van Cauwenberghe; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mamm Genome       Date:  2016-05-03       Impact factor: 2.957

Review 8.  Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.

Authors:  Andrew B Knott; Ella Bossy-Wetzel
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 10.  Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2012-08-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.